Literature DB >> 16990849

A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells.

J Yu1, V Baron, D Mercola, T Mustelin, E D Adamson.   

Abstract

p73, a transcription factor rarely mutated in cancer, regulates a subset of p53 target genes that cause cells to respond to genotoxic stress by growth arrest and apoptosis. p73 is produced in two main forms; only TAp73 reiterates the roles of p53, while DeltaNp73 can be oncogenic in character. We show that the TAp73 form produced by TP73 P1 promoter has five distinct Egr1-binding sites, each contributing to the transcriptional upregulation of TAp73 by Egr1 in several cell types. In contrast, TP73 P2 promoter transcribes DeltaNp73, is not induced by Egr1, but is induced by TAp73 and p53. Induction of TAp73 by genotoxic stress requires Egr1 in mouse in vivo. Newly discovered non-consensus p53-binding sites in p73, p53 and Egr1 promoters reveal inter-regulating networks and sustained expression by feedback loops in response to stress, resulting in prolonged expression of the p53 family of genes and efficient apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990849     DOI: 10.1038/sj.cdd.4402029

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  48 in total

1.  Mechanisms of crystalline silica-induced pulmonary toxicity revealed by global gene expression profiling.

Authors:  Rajendran Sellamuthu; Christina Umbright; Shengqiao Li; Michael Kashon; Pius Joseph
Journal:  Inhal Toxicol       Date:  2011-11-16       Impact factor: 2.724

2.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

3.  Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.

Authors:  David N Boone; Ying Qi; Zhaoliang Li; Stephen R Hann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype.

Authors:  Nir Ben-Chetrit; Gabi Tarcic; Yosef Yarden
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

5.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

6.  Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73.

Authors:  Joseph R Evans; Joshua D Bosman; Lauren Brown-Endres; Fruma Yehiely; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2009-09-24       Impact factor: 4.872

7.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

8.  Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells.

Authors:  L Sauer; D Gitenay; C Vo; V T Baron
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

9.  Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip.

Authors:  Shilpi Arora; Yipeng Wang; Zhenyu Jia; Saynur Vardar-Sengul; Ayla Munawar; Kutbuddin S Doctor; Michael Birrer; Michael McClelland; Eileen Adamson; Dan Mercola
Journal:  Genome Biol       Date:  2008-11-25       Impact factor: 13.583

10.  HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Authors:  L Plowright; K J Harrington; H S Pandha; R Morgan
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.